Zobrazeno 1 - 10
of 35
pro vyhledávání: '"Emilie Soularue"'
Autor:
Angélique Vienot, Marion Jacquin, Magali Rebucci-Peixoto, Dimitri Pureur, François Ghiringhelli, Eric Assenat, Pascal Hammel, Olivier Rosmorduc, Morgane Stouvenot, Manon Allaire, Mohamed Bouattour, Hélène Regnault, Serge Fratte, Eric Raymond, Emilie Soularue, Stéphanie Husson-Wetzel, Vincent Di Martino, Allison Muller, Anne-Laure Clairet, Christine Fagnoni-Legat, Olivier Adotevi, Aurélia Meurisse, Dewi Vernerey, Christophe Borg
Publikováno v:
BMC Cancer, Vol 23, Iss 1, Pp 1-9 (2023)
Abstract Background Several cancer immunotherapies that target the PD-L1/PD-1 pathway show promising clinical activity in patients with hepatocellular carcinoma (HCC). However, the standard of care in first-line treatment with atezolizumab (anti-PD-L
Externí odkaz:
https://doaj.org/article/39a0fdecdfae4b14bb524649b02db940
Autor:
Clélia Coutzac, Jean-Mehdi Jouniaux, Angelo Paci, Julien Schmidt, Domenico Mallardo, Atmane Seck, Vahe Asvatourian, Lydie Cassard, Patrick Saulnier, Ludovic Lacroix, Paul-Louis Woerther, Aurore Vozy, Marie Naigeon, Laetitia Nebot-Bral, Mélanie Desbois, Ester Simeone, Christine Mateus, Lisa Boselli, Jonathan Grivel, Emilie Soularue, Patricia Lepage, Franck Carbonnel, Paolo Antonio Ascierto, Caroline Robert, Nathalie Chaput
Publikováno v:
Nature Communications, Vol 11, Iss 1, Pp 1-13 (2020)
The gut microbiota has been reported to regulate the efficacy of cancer therapy. Here, the authors show that short-chain fatty acids, which are generated through bacterial fermentation, increases immune tolerance leading to resistance to anti-CTLA-4
Externí odkaz:
https://doaj.org/article/1117fcdf2fd44e30b8bbaa1e829d3ecf
Autor:
Camille Evrard, Thomas Aparicio, Emilie Soularue, Karine Le Malicot, Jérôme Desramé, Damien Botsen, Farid El Hajbi, Daniel Gonzalez, Come Lepage, Olivier Bouché, David Tougeron, on behalf of the DURIGAST—PRODIGE 59 Investigators/Collaborators
Publikováno v:
Biomedicines, Vol 10, Iss 5, p 1211 (2022)
Efficacy of immune checkpoint inhibitors (ICI) as monotherapy in 2nd line treatment for gastric or gastro-oesophageal junction (GEJ) adenocarcinoma is low, with no evaluation of efficacy and safety of ICI combined with chemotherapy. The DURIGAST PROD
Externí odkaz:
https://doaj.org/article/e5f33636db76484d82559bf48a274df7
Autor:
David Piquemal, Roman Bruno, Barbara Bournet, Francois Ghiringhelli, Florian Noguier, Cindy Canivet, Aurélie Bertaut, Fabien Pierrat, Ludovic Evesque, Amelia Gamez, Jerome Cros, Emilie Rederstorff, Erwan Petit, Johan Adnet, Angélique Saint, Antoine Drouillard, Emmanuelle Kempf, Emilie Soularue, Julie Vincent, Isabelle Baumgaertner, Audrey Hennequin, Christophe Tournigand, Daniel Lopez Trabada Ataz, Leila Bengrine, Come Lepage, Sylvain Manfredi, Pauline Afchain, Isabelle Trouilloud, Alice Gagnaire, Noelle K. LoConte, Jean-Baptiste Bachet
Publikováno v:
Journal of Gastrointestinal Oncology. 14:997-1007
Autor:
Anaïs Jenvrin, Audrey Perret, Lola-Jade Palmieri, Emilie Soularue, Chloé Broudin, Bastien Rance, Julien Taieb, Claire Gallois
Publikováno v:
Digestive and Liver Disease.
Autor:
Sylvain Manfredi, Eric Terrebonne, David Malka, Prodige Investigators, Emilie Barbier, Valérie Lebrun Ly, Hervé Perrier, Laetitia Dahan, François Ghiringhelli, Faiza Khemissa Akouz, Emilie Soularue, Thierry Lecomte, Cindy Neuzillet, Jean-Marc Phelip, Yann Molin, Vincent Bourgeois, Samy Louafi, Julien Edeline, Romain Coriat, Jérôme Desramé, Pierre Michel
Publikováno v:
Journal of Clinical Oncology. 40:262-271
PURPOSE Whether triplet chemotherapy is superior to doublet chemotherapy in advanced biliary tract cancer (BTC) is unknown. METHODS In this open-label, randomized phase II-III study, patients with locally advanced or metastatic BTC and an Eastern Coo
Autor:
Sarah Watson, Julien Masliah Planchon, Joanna Cyrta, Pauline Vaflard, Ivan Bièche, François-Clément Bidard, Marine Lefevre, Christophe Louvet, Vincent Servois, Emilie Soularue
Publikováno v:
JCO Precision Oncology. :370-377
Autor:
Clélia Coutzac, Frederic Bibeau, Meher Ben Abdelghani, Thomas Aparicio, Romain Cohen, Elodie Coquan, Olivier Dubreuil, Ludovic Evesque, François Ghiringhelli, Stefano Kim, Samuel Lesourd, Cindy Neuzillet, Jean-Marc Phelip, Guillaume Piessen, Philippe Rochigneux, Emmanuelle Samalin, Emilie Soularue, Yann Touchefeu, David Tougeron, Aziz Zaanan, Christelle de la Fouchardière
Publikováno v:
Digestive and Liver Disease
Digestive and Liver Disease, 2022, 54 (10), pp.1335-1341. ⟨10.1016/j.dld.2022.07.008⟩
Digestive and Liver Disease, 2022, 54 (10), pp.1335-1341. ⟨10.1016/j.dld.2022.07.008⟩
International audience; Background: Immune checkpoint inhibitors (ICI) targeting Programmed death-1 (PD-1) have shown their efficacy in advanced MSI/dMMR (microsatellite instability/deficient mismatch repair) tumors. The MSI/dMMR status predicts clin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f54d5c46065bce3549e79b161db7c16c
https://hal.science/hal-03837196/file/PIIS1590865822005916.pdf
https://hal.science/hal-03837196/file/PIIS1590865822005916.pdf
Autor:
Isabelle Trouilloud, Nabil Baba-Hamed, Marie-Pierre Galais, David Tougeron, Romain Coriat, Jean-Philippe Metges, Olivier Bouché, Jean-Marc Phelip, Lola-Jade Palmieri, Laurent Mineur, Benoit Rousseau, Victoire Granger, Lea Saban-Roche, Pierre Michel, Julie Henriques, Jean-Marc Gornet, Emilie Soularue, Astrid Lièvre, Denis Smith, Dewi Vernery, Stéphane Obled, Gael Goujon, Christophe Locher, Anne-Laure Bignon-Bretagne, Gaetan Des Guetz, Sylvain Manfredi, Solene Doat, Bruno Buecher, Marie Dior, Carole Vitellius, Simon Pernot
Publikováno v:
Oncologist
Oncologist, AlphaMed Press, 2020, 25 (2), ⟨10.1634/theoncologist.2019-0328⟩
The Oncologist
Oncologist, AlphaMed Press, 2020, 25 (2), ⟨10.1634/theoncologist.2019-0328⟩
The Oncologist
Background Patients with RAS wild‐type (WT) nonresectable metastatic colorectal cancer (mCRC) may receive either bevacizumab or an anti‐epidermal growth factor receptor (EGFR) combined with first‐line, 5‐fluorouracil‐based chemotherapy. Wit
Autor:
Emilie Hafliger, Alessandra Boccaccino, Alexandra Lapeyre-Prost, Audrey Perret, Claire Gallois, Maria Antista, Lorenzo Pilla, Thierry Lecomte, Mario Scartozzi, Emilie Soularue, Lisa Salvatore, Vincent Bourgeois, Massimiliano Salati, David Tougeron, Ludovic Evesque, Jean-Nicolas Vaillant, Reem El-Khoury, Sara Lonardi, Chiara Cremolini, Julien Taieb
Publikováno v:
European journal of cancer (Oxford, England : 1990). 168
Encorafenib plus cetuximab is efficient in anti-EGFR-naïve patients with BRAFWe retrospectively collected a series of patients with BRAFm mCRC treated with B + E after previous anti-EGFR treatment, in 14 centers. Progression-free survival (PFS) and